| | FREE WEBINAR: Decoding the Vaginal Microbiome Don't miss the chance to hear Priyanka Jain, CEO & Co-Founder at Evvy discuss their mission to close the gender health gap by leveraging overlooked biomarkers and using metagenomic sequencing to better understand the vaginal microbiome. Register Now! |
|---|
Novartis suspends dosing in phase 2b Huntington's trial after side effects reported Chasing GSK, Pfizer races to regulators after RSV vaccine paints positive impression in RENOIR phase 3 Aktis makes waves with $84M extension as 3 big pharmas channel funds to radiopharmaceutical pipeline UPDATED: PACT Pharma to cull lead asset, divert 54 employees to new business development venture Westlake backs 3T to use Stanford tech to land one-two punch on TCR challenges AbbVie, J&J's Imbruvica wins first pediatric nod, this one for chronic graft-versus-host disease Open Orphan inks £10.4M deal to produce new H1N1 challenge virus It's a spinoff: Novartis parts ways with Sandoz just as its generics biz shows signs of recovery MIT researchers track Parkinson’s patients using radar as they sleep Worldwide CRO expands with new bioanalytical lab Amazon Care is shutting down at the end of 2022. Here's why Featured Story | By Gabrielle Masson After seeing signs of side effects in some participants, Novartis has suspended dosing in its phase 2b Huntington’s disease trial assessing branaplam. Specifically, the review found that branaplam may cause peripheral neuropathy. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Pfizer has kept up the heat on GSK in the respiratory syncytial virus (RSV) vaccine race, joining its rival in posting positive phase 3 data and staying tucked in its slipstream with plans to seek approval in the fall. read more By Gabrielle Masson Aktis Oncology has closed a series A extension round to the tune of $84 million, with big pharmas Merck Novartis and BMS joining to expand the biotech’s bandwidth for developing radiopharmaceutical cancer treatments. read more By Max Bayer More than a month after axing 94 employees, PACT Pharma is culling its lead asset and diverting 54 of the laid-off employees to a new business development venture that's yet to be named. read more By Nick Paul Taylor 3T Biosciences has stepped out of the shadows equipped with $40 million in series A cash and a platform designed to address two major challenges in T-cell-receptor-based therapeutics. Armed with the cash, the West Coast biotech plans to advance a pipeline featuring development-stage TCR-T cell assets. read more By Kevin Dunleavy After nine years on the market and winning 11 FDA approvals, Johnson & Johnson and AbbVie’s Imbruvica has gained its first pediatric nod. This one is for chronic graft-versus-host disease (cGVHD) and gives children ages 1 to 11 their first treatment option for the life-threatening disorder. The FDA first signed off on Imbruvica’s use for those 12 and older with cGVHD in 2017. read more By Joseph Keenan Open Orphan subsidiary hVIVO has inked a 10.4 million pound sterling ($12.3 million) deal with a large, unnamed pharmaceutical company to produce a novel batch of H1N1 influenza challenge virus. read more By Angus Liu Less than a year into a strategic review, Novartis has decided to spin off its generics unit Sandoz. The separation will allow both companies to pursue different capital allocation strategies, CEO Vas Narasimhan, M.D., said. read more By Conor Hale The AI system analyzes a sleeping person's breathing patterns for some of the earliest signs of Parkinson’s or to note changes in the severity of the disease over time. read more By Joseph Keenan Worldwide Clinical Trials, a North Carolina-based CRO, is expanding its services with a new 15,000-square-foot bioanalytical laboratory at its Austin, Texas, location. read more By Heather Landi Three years after it began piloting a primary care service for its employees that blended telehealth and in-person medical services, Amazon plans to shutter its Amazon Care service for employers. read more Resources Sponsored by: Ferma.AI, a Product of ZoomRx Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Events Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Free Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Drug Development Boot Camp® 2022 November 16-17, 2022 |
